• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Insulet’s Q3 sales rise, operating losses narrow as it up its full-year guidance

Insulet’s Q3 sales rise, operating losses narrow as it up its full-year guidance

October 26, 2009 By MassDevice staff

Insulet Corp. posted strong third-quarter results, with increased revenues and narrower operating losses, prompting the Bedford, Mass.-based firm to increase its full-year sales and earnings forecasts.

The insulin management system maker posted revenues of $18.7 million during the three months ended Sept. 30, up 85.3 percent compared with $10.1 million during the same period last year.

Net losses widened to $24.7 million, up 14 percent compared with $21.7 million during Q3 2008, but operating losses narrowed by 32 percent, falling from $19.8 million during the third quarter last year to $13.5 million during the just-ended quarter.

The gains came as Insulet slashed total operating expenses by more than 92 percent as a percentage of revenues, via reductions in research and development costs (down 14 percent as a percentage of revenues); general and administrative expenses (down 29 percent as a percentage of revenues); and sales and marketing costs (which fell nearly 50 percent as a percentage of revenues).

Insulet made another significant financial move during the quarter, amending its $60 million credit facility with Deerfield Management Co. in a move it said would save $12 million over three years.

The original deal, inked in March, called for the company to borrow $27.5 million, with another $32.5 million available at Insulet’s discretion.

The amended deal will see Insulet repay that nut with 2,855,659 shares of stock for $9.63 per share — a 6 percent discount from its $10.28 Sept. 25 closing price.

For its part, Deerfield agreed to eliminate performance-based milestones on the remaining $32.5 million, reduce the annual interest rate to 8.5 percent from 9.75 percent and forego the remaining 1.5 million warrants that would have been issued on future draws.

Insulet said it will draw down the remaining $32.5 million immediately; the entire $60 million nut, plus interest, is still due in Sept. 2012.

The positive third-quarter results led to Insulet increasing its full-year sales and earnings forecasts. The company is now predicting sales of between $64 million and $66 million, compared with prior expectations of between $58 million and $65 million. Operating losses are now expected to be between $58 million and $60 million for fiscal 2009, compared to previous guidance of $55 million to $60 million.

Filed Under: Business/Financial News, MassDevice Earnings Roundup Tagged With: Insulin Management

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy